Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 23;12:708820. doi: 10.3389/fimmu.2021.708820

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Strafella, Caputo, Guerrera, Termine, Fabrizio, Cascella, Picozza, Caltagirone, Rossini, Balice, Salvia, Battistini, Borsellino and Giardina

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Virological and immunological profiling showing the infection trajectory observed in the patient. (A) Sars-CoV-2 genomic RNA and sg-mRNA component expressed in log10copies/mL are reported for each molecular test performed during the time of infection. (B) Slopes representation indicating the speed of temporal decay observed in the patient compared to reference samples, with wild-type or variant Sars-CoV-2. (C) Titers of Anti-Sars-CoV-2 RBD antibodies (i.e neutralizing Abs) measured 26 days post vaccination, 54 days post vaccination (day 2 post infection) and 62 days post vaccination (day 9 post infection). (D) Assessment of Antibodies subpopulations ratios measured at the three time-points of interest.